These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 6187080)

  • 21. Effects of intraperitoneal administration of OK-432 for patients with advanced cancer.
    Toge T; Yamada H; Aratani K; Kameda A; Kuroi K; Hisamatsu K; Hattori T
    Jpn J Surg; 1985 Jul; 15(4):260-5. PubMed ID: 2932585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of malignant ascites and pleurisy by a streptococcal preparation OK-432 with fresh frozen plasma--a mechanism of polymorphonuclear leukocyte (PMN) accumulation.
    Kato H; Yamamura Y; Kin R; Tanigawa M; Sano H; Inoue M; Sugino S; Kondo M
    Int J Immunopharmacol; 1989; 11(2):117-28. PubMed ID: 2539336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus interleukin-2: induction of autologous tumor-reactive CD4+ Th1 killer lymphocytes.
    Yamaguchi Y; Miyahara E; Ohshita A; Kawabuchi Y; Ohta K; Shimizu K; Minami K; Hihara J; Sawamura A; Toge T
    Br J Cancer; 2003 Nov; 89(10):1876-84. PubMed ID: 14612896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advanced ovarian cancer treated by intraperitoneal immunotherapy with OK-432.
    Kawagoe K; Masuda H
    Jpn J Clin Oncol; 1986 Jun; 16(2):137-42. PubMed ID: 3735703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The effect of OK-432 in the treatment of primary lung cancer].
    Kishimoto T; Okada K
    Gan To Kagaku Ryoho; 1987 Apr; 14(4):1051-6. PubMed ID: 3494430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Influence of OK 432 upon postoperative alteration in activities producing lymphokines, IL 1, IL 2, and IFN, of peripheral blood mononuclear cells derived from patients with gastric cancer].
    Hosoi J
    Nihon Gan Chiryo Gakkai Shi; 1987 Apr; 22(3):603-13. PubMed ID: 2443588
    [No Abstract]   [Full Text] [Related]  

  • 27. Neutrophil-mediated tumor cell destruction in cancer ascites. II. A OK-432 attracts killer neutrophils through activation of complement C5.
    Fujimura T; Torisu M
    Clin Immunol Immunopathol; 1987 May; 43(2):174-84. PubMed ID: 3105938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Management of malignant ascites by intraperitoneal injection of OK-432. Possible mechanism of the reduction of original tumor mass volume].
    Katano M; Mizoguchi T; Yamamoto H; Hisatsugu T; Torisu M
    Nihon Geka Gakkai Zasshi; 1987 Dec; 88(12):1676-83. PubMed ID: 3447033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Immunotherapy, with OK-432 for cases of nasopharyngeal carcinoma].
    Tsukuda M; Tamamushi N; Mochimatsu I; Mitarai K; Kaneko M; Sawaki S
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):53-9. PubMed ID: 3942399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The influence of a biological response modifier on thoracic lymphocytes--a study involving clinical cases and animal experiments].
    Hanaue H; Kurosawa T; Miyakawa S; Kitano Y; Nemoto A; Yamoto H; Asagoe T; Shikata J
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1285-9. PubMed ID: 3488025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Immunohistological studies of the skin at the injection site of cases receiving the streptococcal agent OK-432].
    Hanaue H; Kurosawa T; Miyakawa S; Horie F; Nemoto A; Yamoto H; Nishimura S; Tsuchiya H; Miura S; Asagoe T
    Nihon Gan Chiryo Gakkai Shi; 1985 Dec; 20(10):2271-8. PubMed ID: 3879494
    [No Abstract]   [Full Text] [Related]  

  • 32. [Adoptive immunotherapy of murine tumors using cultured syngeneic tumor-bearer-spleen cells. II: Therapeutic effect of cultured lymphocytes against malignant ascites and its augmentation by the streptococcal preparation, OK 432].
    Kan N; Inamoto T; Hori T; Nio Y; Tsuchitani T; Kodama H; Tobe T; Ohgaki K
    Nihon Gan Chiryo Gakkai Shi; 1985 May; 20(4):784-96. PubMed ID: 3877129
    [No Abstract]   [Full Text] [Related]  

  • 33. [Clinical significance of a skin test (SU-PS) for immune responses in patients with gastrointestinal cancer treated with OK-432].
    Miyamoto Y; Takeshita M; Izuo M
    Gan To Kagaku Ryoho; 1986 Oct; 13(11):3229-35. PubMed ID: 3777960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical evaluation of immunochemotherapy with streptococcal preparation "OK-432" on inoperable advanced cancers (author's transl)].
    Nio Y; Nitta N; Tanaka A; Ichikawa T; Henmi K
    Nihon Geka Hokan; 1981 Sep; 50(5):704-10. PubMed ID: 7332399
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of biological response modifier on thoracic duct lymphocytes in recurrent gastric cancer. Evaluation of OK-432, a hemolytic streptococcus preparation.
    Hanaue H; Kim DY; Kubota M; Kurosawa T; Shikata J; Kondoh Y; Ogoshi K; Makuuchi H; Nakasaki H; Mitomi T
    Tokai J Exp Clin Med; 1987 May; 12(2):97-102. PubMed ID: 3502432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Nursing of a patient with ascites being treated with OK-432].
    Yamashita I; Hidaka M; Ikegawa H; Yuhara K; Mori C
    Kango Gijutsu; 1989 Mar; 35(4):412-5. PubMed ID: 2754876
    [No Abstract]   [Full Text] [Related]  

  • 37. [Response to OK-432 (picibanil) in cancer patients and change of immunological parameters for the administration of OK-432 (picibanil)].
    Kato K
    Nihon Jibiinkoka Gakkai Kaiho; 1988 Feb; 91(2):215-24. PubMed ID: 3373373
    [No Abstract]   [Full Text] [Related]  

  • 38. [Clinical significance of Su-polysaccharide (Su-PS) skin test in patients with primary lung cancer treated with chemotherapy and administration of OK-432, with special reference to the therapeutic effect and prognosis].
    Horiuchi M; Sato K; Nakarai I; Shinoda A
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):468-74. PubMed ID: 2181937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction of suppressor cells in cancer patients treated with OK-432 immunotherapy.
    Uchida A; Hoshino T
    Int J Cancer; 1980 Oct; 26(4):401-4. PubMed ID: 6454666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy of patients with terminal-stage malignant tumors with an immunopotentiator OK-432--a comparison of SU-PS test-responding and -nonresponding patients.
    Yagi Y; Yagi S
    Int J Immunopharmacol; 1988; 10(4):451-61. PubMed ID: 3049405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.